Bristol-Myers Squibb Opdivo: Immunotherapy mainstay for advanced cancers

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 9:35:52 PM ET. Details in the imprint.

Opdivo (generic name nivolumab) from Bristol-Myers Squibb is one of the most established immune checkpoint inhibitors in oncology, used to treat a range of advanced solid tumors and blood cancers in the United States. It is approved as a monotherapy and in combination with other agents such as ipilimumab in indications including advanced melanoma, non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, and several additional cancer types. For many U.S. patients, Opdivo is now a standard-of-care option once disease reaches an advanced or metastatic stage, typically administered in hospital outpatient or infusion center settings under oncologist supervision.

What Opdivo does and how it is used in practice

Opdivo is a human IgG4 monoclonal antibody that targets the programmed death-1 (PD-1) receptor on T cells, blocking its interaction with the PD-L1 and PD-L2 ligands expressed on tumor and immune cells. By inhibiting the PD-1 pathway, Opdivo releases an inhibitory brake on cytotoxic T lymphocytes, allowing the immune system to recognize and attack cancer cells more effectively. This mechanism is similar to other PD-1/PD-L1 inhibitors, but Opdivo was among the earliest drugs in the class to gain broad regulatory approvals, and it has accumulated extensive real-world and trial data across many tumor types.

In the U.S., Opdivo dosing and schedules vary by indication and whether it is used alone or in combination with other drugs. For example, certain regimens for advanced non-small cell lung cancer rely on weight-based dosing every two or four weeks administered intravenously over approximately 30 minutes in a clinical setting. In melanoma and renal cell carcinoma, combination regimens with Yervoy (ipilimumab) use an induction phase where both antibodies are administered, followed by Opdivo maintenance monotherapy. Such combination protocols are designed to leverage complementary immune-modulating mechanisms, with ipilimumab targeting CTLA-4 and Opdivo targeting PD-1.

Because Opdivo stimulates immune activity, its side-effect profile centers on immune-related adverse events. These can include inflammation of organs such as the lungs (pneumonitis), colon (colitis), liver (hepatitis), endocrine glands (thyroiditis or hypophysitis), and skin rash or pruritus. Management typically involves dose delays, corticosteroids, or permanent discontinuation depending on severity, following detailed prescribing information and oncology practice guidelines. Routine monitoring of organ function and careful assessment of new symptoms are standard in U.S. oncology centers using PD-1 inhibitors.

Access to Opdivo in the U.S. is driven primarily through oncologist prescription, with reimbursement typically coordinated via commercial insurers, Medicare, or Medicaid for eligible indications. Bristol-Myers Squibb operates patient-support and copay-assistance programs designed to help patients navigate insurance approvals and out-of-pocket costs, especially in high-cost indications where multi-drug combinations and long-term therapy can lead to substantial cumulative spending. In parallel, many major U.S. cancer centers and community practices incorporate Opdivo-containing regimens into their treatment algorithms when supported by clinical trial evidence and guidelines from organizations such as the National Comprehensive Cancer Network.

In summary, Opdivo is a long-standing and widely used immunotherapy in Bristol-Myers Squibb's oncology portfolio, with broad U.S. availability across multiple tumor types and a significant body of safety and efficacy data. As one of the company’s key growth and replacement therapies relative to older small-molecule drugs, it plays an important strategic role within the broader shift toward biologics and immuno-oncology. Shares of Bristol-Myers Squibb (US1078421011, ticker BMY) traded at $55.60 on the NYSE on June 12, 2026.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.